Bicyclo Ring System Which Contains The Hetero Ring As One Of The Cyclos Patents (Class 540/523)
-
Publication number: 20130158256Abstract: Process for the synthesis of ivabradine of formula (I): addition salts thereof with a pharmaceutically acceptable acid, and hydrates thereof.Type: ApplicationFiled: November 9, 2012Publication date: June 20, 2013Applicant: LES LABORATOIRES SERVIERInventors: Jean-Luc RENAUD, Nicolas Pannetier, Jean-Pierre Lecouve, Lucile Vaysse-Ludot, Solenne Moulin
-
Publication number: 20130158257Abstract: Process for the synthesis of ivabradine of formula (I): addition salts thereof with a pharmaceutically acceptable acid, and hydrates thereof.Type: ApplicationFiled: December 14, 2012Publication date: June 20, 2013Applicant: LES LABORATOIRES SERVIERInventor: LES LABORATOIRES SERVIER
-
Publication number: 20130116213Abstract: The present invention relates to a novel fused pyrimidine derivative having an inhibitory activity for tyrosine kinases, and a pharmaceutical composition for preventing or treating cancers, tumors, inflammatory diseases, autoimmune diseases, or immunologically mediated diseases comprising same as an active ingredient.Type: ApplicationFiled: June 20, 2011Publication date: May 9, 2013Applicant: HANMI SCIENCE CO., LTD.Inventors: Mi Young Cha, Seok Jong Kang, Mi Ra Kim, Ju Yeon Lee, Ji Young Jeon, Myoung Gi Jo, Eun Joo Kwak, Kwang Ok Lee, Tae Hee Ha, Kwee Hyun Suh, Maeng Sup Kim
-
Publication number: 20130116239Abstract: The present invention relates to pharmaceutical compositions with delayed release which contain ivabradine adipate as active substance. The present invention furthermore relates to processes for the preparation of this composition and certain salts of ivabradine.Type: ApplicationFiled: June 14, 2011Publication date: May 9, 2013Applicant: ratiopharm GnbHInventors: Ramesh Matioram Gidwani, Mayur Vilas Kolhatkar, Dominique Meergans, Ralph Stefan, Jens Geier
-
Publication number: 20130109672Abstract: Disclosed are pyruvate kinase M2 activators which are compounds of Formula (I), including those of Formula (II), wherein A1, A2, L, R, R1 to R3, X1 to X3, k, n, and m are as defined herein, that are useful in treating a number of diseases that are treatable by the activation of PKM2, for example, cancer. A1-NR-L-A2 (I).Type: ApplicationFiled: April 26, 2011Publication date: May 2, 2013Applicant: The United States of America,as represented by the Secretary, Department of Health and Human ServiceInventors: Matthew B. Boxer, Min Shen, Douglas S. Auld, Craig J. Thomas, Martin J. Walsh
-
N3-HETEROARYL SUBSTITUTED TRIAZOLES AND N5-HETEROARYL SUBSTITUTED TRIAZOLES USEFUL AS AXL INHIBITORS
Publication number: 20130090330Abstract: N3-Heteroaryl substituted triazoles and N5-heteroaryl substituted triazoles and pharmaceutical compositions containing the compounds are disclosed as being useful in inhibiting the activity of the receptor protein tyrosine kinase Axl. Methods of using the compounds in treating diseases or conditions associated with Axl activity are also disclosed.Type: ApplicationFiled: October 4, 2012Publication date: April 11, 2013Applicant: RIGEL PHARMACEUTICALS, INC.Inventor: RIGEL PHARMACEUTICALS, INC. -
Patent number: 8415468Abstract: Process for the synthesis of ivabradine of formula (I): and addition salts thereof with a pharmaceutically acceptable acid.Type: GrantFiled: February 3, 2010Date of Patent: April 9, 2013Assignee: Les Laboratoires ServierInventors: Jean-Louis Peglion, Aimee Dessinges, Bernard Serkiz, Jean-Michel Lerestif, Jean-Pierre Lecouve
-
Publication number: 20130084332Abstract: This application relates to taste masked multi-layered particles an inert core, one or more coating layer(s) comprising a pharmaceutically active ingredient and a binder, an intermediate coating layer (seal coating) free from a low molecular weight water-soluble ionic compound and comprising a water-soluble pharmaceutical film-forming compound selected from (i) HPMC and PEG or (ii) PVP, and an outer coating layer (final or taste masking coating) free from a low molecular weight water-soluble ionic compound and comprising (i) a poly(meth)acrylate or (ii) a mixture comprising 60-90% (w/w) EC and 10-40% (w/w) HPMC, wherein the pharmaceutically active ingredient is water-soluble and comprises either at least one basic group and/or a bitter taste. Further disclosed are methods for the production of such particles and pharmaceutical compositions comprising them.Type: ApplicationFiled: August 13, 2012Publication date: April 4, 2013Applicant: BOEHRINGER INGELHEIM VETMEDICA GMBHInventors: Martin FOLGER, Stefan LEHNER, Annette GRAVE, Norbert POELLINGER, Randolph Seidler
-
Patent number: 8377922Abstract: The present invention relates to a benzazepinone compound represented by the following formula (I): wherein R1 represents a C1-C6 alkyl group or halogeno C1-C6 alkyl group, R2 represents a carboxyl group which may be protected, and Y represents a group represented by the formula (II): wherein Z represents CH or a nitrogen atom, or a pharmaceutically acceptable salt thereof.Type: GrantFiled: November 14, 2008Date of Patent: February 19, 2013Assignee: Ube Industries, Ltd.Inventors: Naoto Suzuki, Yasunori Tsuzaki, Kimihiko Yoshimura, Masahiko Hagihara, Yukinori Wada, Masao Maruyama, Nobuyoshi Fujii, Yasuhiro Aga
-
Publication number: 20120329780Abstract: The present invention relates to novel compounds of formula (I) that are capable of inhibiting one or more kinases, especially SYK (Spleen Tyrosine Kinase), LRRK2 (Leucine-rich repeat kinase 2) and/or MYLK (Myosin light chain kinase) or mutants thereof. The compounds find applications in the treatment of a variety of diseases. These diseases include autoimmune diseases, inflammatory diseases, bone diseases, metabolic diseases, neurological and neurodegenerative diseases, cancer, cardiovascular diseases, allergies, asthma, alzheimer's disease, parkinson's disease, skin disorders, eye diseases, infectious diseases and hormone-related diseases.Type: ApplicationFiled: April 23, 2012Publication date: December 27, 2012Applicant: Origenis GmbHInventors: Michael Thormann, Andreas Treml, Michael Almstetter, Nadine Traube
-
Patent number: 8329682Abstract: The invention provides new pyrrolo-nitrogenous heterocyclic derivatives represented by formula (I) or their salts, the preparation thereof, pharmaceutical compositions containing such derivatives and the use of such derivatives as therapeutic agents, especially as protein kinase inhibitors, wherein each substituent in formula (I) is same as defined in the description.Type: GrantFiled: May 14, 2008Date of Patent: December 11, 2012Assignee: Shanghai Hengrui Pharmaceutical Co., Ltd.Inventors: Peng Cho Tang, Yidong Su, Yali Li, Lei Zhang, Fuqiang Zhao, Jialiang Yang, Ying Zhou, Pingyan Bie, Guangtao Qian, Minggang Ju
-
Patent number: 8299059Abstract: A form of crystalline (2S)-2-hydroxy-3-methyl-N-[(1S)-1-methyl-2-oxo-2-[[(1S)-2,3,4,5-tetrahydro-3-methyl-2-oxo-1H-3-benzazepin-1-yl]amino]ethyl]-butanamide anhydrate Form II having improved flowability and drug-loading properties and a process for its preparation.Type: GrantFiled: October 29, 2010Date of Patent: October 30, 2012Assignee: Eli Lilly and CompanyInventor: Christopher Luis Burcham
-
Publication number: 20120258929Abstract: The present invention provides an agent that modulates physiological condition of pests, wherein the agent has an ability to modulate the activity of an insect peptidyl-dipeptidase A; a method for assaying pesticidal activity of a test substance, which comprises a step of measuring the activity of a peptidyl-dipeptidase A in a reaction system in which the peptidyl-dipeptidase A contacts with a test substance, and the like.Type: ApplicationFiled: June 23, 2006Publication date: October 11, 2012Applicant: SUMITOMO CHEMICAL COMPANY, LIMITEDInventors: Yasutaka Shimokawatoko, Marc Van De Craen, Irene Nooren, Sandra Turconi, Yann Naudet, Guy Nys, Jurgen Debaveye
-
Patent number: 8278440Abstract: Process for the synthesis of ivabradine of formula (I): and addition salts thereof with a pharmaceutically acceptable acid.Type: GrantFiled: February 15, 2011Date of Patent: October 2, 2012Assignee: Les Laboratoires ServierInventors: Jean-Louis Peglion, Pascal Caignard
-
Publication number: 20120208996Abstract: Process for the synthesis of ivabradine of formula (I): and addition salts thereof with a pharmaceutically acceptable acid.Type: ApplicationFiled: February 9, 2012Publication date: August 16, 2012Applicant: LES LABORATOIRES SERVIERInventors: Jean-Louis PEGLION, Aimée DESSINGES
-
Publication number: 20120172589Abstract: Process for the synthesis of ivabradine of formula (I): and addition salts thereof with a pharmaceutically acceptable acid.Type: ApplicationFiled: September 17, 2010Publication date: July 5, 2012Applicant: LES LABORATOIRES SERVIERInventors: Jean-Louis Peglion, Pascal Caignard, Jean-Michel Lerestif, Jean-Pierre Lecouve
-
Patent number: 8212026Abstract: The present invention encompasses a process for the preparation of highly pure ivabradine hydrochloride by treating ivabradine with alcoholic hydrogen chloride. The invention further encompasses amorphous ivabradine hydrochloride and process for its preparation using suitable acid addition salts of ivabradine.Type: GrantFiled: May 29, 2008Date of Patent: July 3, 2012Assignee: Ind-Swift Laboratories LimitedInventors: Satyendra Pal Singh, Gajendra Singh, Lalit Wadhwa
-
Publication number: 20120165519Abstract: The present invention provides a compound of formula I or II or a pharmaceutically acceptable salt form thereof, wherein R1, R2, R3, R4, R5, A1, A2, A3, A4, and A5, are as defined herein. The compounds of formula I or II have ALK and/or c-Met inhibitory activity, and may be used to treat proliferative disorders.Type: ApplicationFiled: March 6, 2012Publication date: June 28, 2012Applicant: Cephalon, Inc.Inventors: Gulzar Ahmed, Henry Joseph Breslin, Jason Burke, Matthew A. Curry, James L. Diebold, Bruce Dorsey, Benjamin J. Dugan, Daming Feng, Diane E. Gingrich, Tao Guo, Keith S. Learn, Joseph G. Lisko, Rong-qiang Liu, Eugen Mesaros, Karen Milkiewicz, Gregory R. Ott, Jay P. Theroff, Tho V. Thieu, Rabindranath Tripathy, Theodore L. Underiner, Gregory J. Wells, Craig A. Zificsak
-
Patent number: 8173813Abstract: The present invention features quinolones, tetrahydroquinolines, and related compounds that inhibit nitric oxide synthase (NOS), particularly those that selectively inhibit neuronal nitric oxide synthase (nNOS) in preference to other NOS isoforms. The NOS inhibitors of the invention, alone or in combination with other pharmaceutically active agents, can be used for treating or preventing various medical conditions.Type: GrantFiled: March 24, 2008Date of Patent: May 8, 2012Assignee: NeurAxon, Inc.Inventors: Shawn Maddaford, Jailall Ramnauth, Suman Rakhit, Joanne Patman, Subhash C. Annedi, John Andrews, Peter Dove, Sarah Silverman, Paul Renton
-
Publication number: 20120095215Abstract: The present invention is to provide a medical composition for the treatment or prophylaxis of diseases caused by angiogenesis of eyes which comprises a compound represented by the following formula (I): wherein R1 represents a C1-C6 alkyl group or halogeno-C1-C6alkyl group, R2 represents a carboxyl group which may be protected, and Y represents a group represented by the formula (II): wherein Z represents CH or nitrogen atom, or a pharmaceutically acceptable salt thereof as an active ingredient.Type: ApplicationFiled: March 30, 2010Publication date: April 19, 2012Applicant: UBE INDUSTRIES, LTD.Inventors: Masahiko Hagihara, Yasuhiro Aga, Tohru Hasegawa
-
Patent number: 8119794Abstract: Process for the synthesis of ivabradine of formula (I): and addition salts thereof with a pharmaceutically acceptable acid.Type: GrantFiled: March 29, 2010Date of Patent: February 21, 2012Assignee: Les Laboratoires ServierInventors: Jean-Louis Peglion, Aimee Dessinges, Bernard Serkiz
-
Publication number: 20120028920Abstract: A heterocyclic compound or a salt thereof represented by the formula (1): where R2 represents a hydrogen atom or a lower alkyl group; A represents a lower alkylene group or lower alkenylene group; and R1 represents an aromatic group or a heterocyclic group. The compound of the present invention has a wide treatment spectrum for mental disorders including central nervous system disorders, no side effects and high safety.Type: ApplicationFiled: October 11, 2011Publication date: February 2, 2012Inventors: Hiroshi YAMASHITA, Hideaki Kuroda, Nobuaki Ito, Shin Miyamura, Kunio Oshima, Jun Matsubara, Haruka Takahashi, Tae Fukushima, Satoshi Shimizu, Kazumi Kondo, Yohji Sakurai, Takeshi Kuroda, Shinichi Taira, Motohiro Itotani, Tatsuyoshi Tanaka
-
Publication number: 20120028919Abstract: The present invention provides a compound of formula I or a salt form thereof, wherein Q1, Q2, Q3, and Q4 are as defined herein. The compound of formula I has ALK and/or JAK2 inhibitory activity, and may be used to treat proliferative disorders.Type: ApplicationFiled: June 15, 2011Publication date: February 2, 2012Applicant: CEPHALON, INC.Inventors: Henry J. Breslin, Sankar Chatterjee, James L. Diebold, Bruce D. Dorsey, Derek D. Dunn, Diane E. Gingrich, Greg A. Hostetler, Robert L. Hudkins, Rachael Hunter, Kurt A. Josef, Joseph Lisko, Eugen F. Mesaros, Karen L. Milkiewicz, Gregory R. Ott, Babu G. Sundar, Jay P. Theroff, Tho Thieu, Rabindranath Tripathy, Theodore L. Underiner, Linda Weinberg, Gregory J. Wells, Craig A. Zificsak
-
Publication number: 20120022044Abstract: According to the invention there is provided a compound of formula I or a pharmaceutically acceptable salt or hydrate thereof; wherein the variables are as defined herein. The compounds selectively attenuate the production of A?42 and hence are useful in treatment of Alzheimer's disease and related conditions.Type: ApplicationFiled: December 7, 2009Publication date: January 26, 2012Inventors: Christian Fischer, Joey Methot, Hua Zhou, Adam J. Schell, Benito Munoz, Alexey A. Rivkin, Sean P. Ahearn, Stephanie Chichetti, Rachel N. MacCoss, Sam Kattar, Matthew Christopher, Chaomin Li, Andrew Rosenau, William Colby Brown
-
Patent number: 8101747Abstract: Process for the synthesis of ivabradine of formula (I): and addition salts thereof with a pharmaceutically acceptable acid.Type: GrantFiled: March 29, 2010Date of Patent: January 24, 2012Assignee: Les Laboratoires ServierInventors: Jean-Louis Peglion, Aimee Dessinges, Bernard Serkiz
-
Patent number: 8097720Abstract: Process for the synthesis of ivabradine of formula (I): and addition salts thereof with a pharmaceutically acceptable acid.Type: GrantFiled: December 23, 2009Date of Patent: January 17, 2012Assignee: Les Laboratories ServerInventors: Jean-Louis Peglion, Aimee Dessinges, Bernard Serkiz, Jean-Michel Lerestif, Jean-Pierre Lecouve
-
Patent number: 8084448Abstract: Compounds of the formula are inhibitors of protein tyrosine phosphatases (PTPases) and, thus, may be employed for the treatment of conditions mediated by PTPase activity. The compounds of the present invention may also be employed as inhibitors of other enzymes characterized with a phosphotyrosine binding region such as the SH2 domain. Accordingly, the compounds of formula (I) may be employed for prevention and/or treatment of insulin resistance associated with obesity, glucose intolerance, diabetes mellitus, hypertension and ischemic diseases of the large and small blood vessels, conditions that accompany type-2 diabetes, including hyperlipidemia, hypertriglyceridemia, atherosclerosis, vascular restenosis, irritable bowel syndrome, pancreatitis, adipose cell tumors and carcinomas such as liposarcoma, dyslipidemia, and other disorders where insulin resistance is indicated.Type: GrantFiled: March 29, 2007Date of Patent: December 27, 2011Assignee: Novartis AGInventors: Alan Neubert, David Barnes, Young-Shin Kwak, Katsumasa Nakajima, Gregory Raymond Bebernitz, Gary Mark Coppola, Louise Kirman, Michael H. Serrano-Wu, Travis Stams, Sidney Wolf Topiol, Thalaththani Ralalage Vedananda, James Richard Wareing
-
Publication number: 20110306596Abstract: The present invention relates to new benzazepine inhibitors of gamma-secretase activity, pharmaceutical compositions thereof, and methods of use thereof.Type: ApplicationFiled: July 19, 2010Publication date: December 15, 2011Applicant: AUSPEX PHARMACEUTICALS, INC.Inventors: Tadimeti Rao, Chengzhi Zhang
-
Publication number: 20110306597Abstract: The present invention relates to compounds of the formula (I) and pharmaceutically acceptable salts and solvates thereof, wherein the substituents are defined herein, to compositions containing such compounds and to the uses of such compounds for the treatment of allergic and respiratory conditions.Type: ApplicationFiled: June 12, 2009Publication date: December 15, 2011Inventors: James Michael Crawforth, Paul Alan Glossop, Bruce Cameron Hamper, Wei Huang, Bradley Elwood Neal, Simon John Mantell, Kirk Olson, Atli Thorarensen, Steve Ronald Turner
-
Patent number: 8076475Abstract: The present invention generally relates to a novel process for preparing vitronectin receptor antagonist compounds having a benzodiazepinyl core structure. This invention relates to the preparation of pharmaceutically active compounds which inhibit the vitronectin receptor and are useful for treatment of inflammation, cancer and cardiovascular disorders, such as atherosclerosis and restenosis, and diseases wherein bone resorption is a factor, such as osteoporosis. In particular, the present invention relates to a novel process for preparing (±)-3-oxo-8-{[3-(pyridin-2-ylamino)propyl]oxy}-2-(2,2,2-trifluoroethyl)-2,3,4,5-tetrahydro-1H-2-benzazepine-4-acetic acid, (R)-3-oxo-8-{[3-(pyridin-2-ylamino)propyl]oxy}-2-(2,2,2-trifluoroethyl)-2,3,4,5-tetrahydro-1H-2-benzazepine-4-acetic acid and (S)-3-oxo-8-{[3-(pyridin-2-ylamino)propyl]oxy}-2-(2,2,2-trifluoroethyl)-2,3,4,5-tetrahydro-1H-2-benzazepine-4-acetic acid or a pharmaceutically acceptable salt thereof.Type: GrantFiled: March 6, 2009Date of Patent: December 13, 2011Assignee: GlaxoSmithKline LLCInventor: Matthew Allen Zajac
-
Publication number: 20110300116Abstract: A method for generating a recombinant clonal cell line expressing a target cell surface receptor at a specific level of expression from a cell population comprising cells transfected with a plasmid encoding the cDNA sequence of the target receptor and expressing the target cell surface receptor, the method comprising (c) incubating the cell population with a receptor specific fluorescent ligand (d) selecting single cells from step (c) expressing the target cell surface receptor by monitoring the specific binding of the fluorescent ligand using flow cytometry; and novel fluorescent ligands.Type: ApplicationFiled: September 29, 2008Publication date: December 8, 2011Applicant: CELLAURA TECHNOLOGIES LTDInventors: Stephen John Hill, Barrie Kellam, Richard John Middleton
-
Patent number: 8071600Abstract: A heterocyclic compound or a salt thereof represented by the formula (1): where R2 represents a hydrogen atom or a lower alkyl group; A represents a lower alkylene group or lower alkenylene group; and R1 represents an aromatic group or a heterocyclic group. The compound of the present invention has a wide treatment spectrum for mental disorders including central nervous system disorders, no side effects and high safety.Type: GrantFiled: August 31, 2006Date of Patent: December 6, 2011Assignee: Otsuka Pharmaceutical Co., Ltd.Inventors: Hiroshi Yamashita, Hideaki Kuroda, Nobuaki Ito, Shin Miyamura, Kunio Oshima, Jun Matsubara, Haruka Takahashi, Tae Fukushima, Satoshi Shimizu, Kazumi Kondo, Yohji Sakurai, Takeshi Kuroda, Shinichi Taira, Motohiro Itotani, Tatsuyoshi Tanaka
-
Publication number: 20110294999Abstract: Process for the synthesis of ivabradine of formula (I): and addition salts thereof with a pharmaceutically acceptable acid.Type: ApplicationFiled: February 3, 2010Publication date: December 1, 2011Applicant: LES LABORATOIRES SERVIERInventors: Jean-Louis Peglion, Aimee Dessinges, Bernard Serkiz, Jean-Michel Lerestif, Jean-Pierre Lecouve
-
Publication number: 20110275614Abstract: Methods for the preparation of Ivabradine sulfate and form I crystal thereof. In particular, the Ivabradine sulfate and the preparation methods thereof, and the stable form I crystal of Ivabradine sulfate and the preparation methods thereof.Type: ApplicationFiled: October 29, 2009Publication date: November 10, 2011Inventors: Piaoyang Sun, Yongjiang Chen, Guangliang Yu
-
Patent number: 8034806Abstract: In one aspect, the invention relates to bicyclic MGluR5 positive allosteric modulators, for example 6-(phenylethynyl)-3,4-dihydroisoquinolin-1(2H)-one, derivatives thereof, and related compounds, which are useful as positive allosteric modulators of the metabotropic glutamate receptor subtype 5 (mGluR5); synthetic methods for making the compounds; pharmaceutical compositions comprising the compounds; and methods of treating neurological and psychiatric disorders associated with glutamate dysfunction using the compounds and compositions. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.Type: GrantFiled: October 31, 2008Date of Patent: October 11, 2011Assignee: Vanderbilt UniversityInventors: P. Jeffrey Conn, Craig W. Lindsley, Charles David Weaver, Alice L. Rodriguez, Colleen M. Niswender, Carrie K. Jones, Richard Williams
-
Patent number: 7994162Abstract: The present invention relates to 2-alkoxy-3,4,5-trihydroxyalkylamide benzodiazepine compounds, to pharmaceutical compositions comprising such compounds, to methods of treatment comprising administering such compounds, to processes for the preparation of such compounds, and to intermediate precursors to such compounds.Type: GrantFiled: November 10, 2008Date of Patent: August 9, 2011Assignee: Sanofi-AventisInventors: Jidong Zhang, Frederico Nardi, Alain Commerçon
-
Publication number: 20110118234Abstract: The present invention provides compounds Formula (I) that are gamma secretase modulators and are therefore useful for the treatment of diseases treatable by modulation of gamma secretase such as Alzheimer's disease. Also provided are pharmaceutical compositions containing such compounds and processes for preparing such compounds.Type: ApplicationFiled: May 4, 2009Publication date: May 19, 2011Inventors: Kaustav Biswas, Jian J. Chen, James R. Falsey, Vijay Keshav Gore, Qingyian Liu, Vu Van Ma, Stephanie J. Mercede, Robert M. Rzasa, Christopher M. Tegley, Jiawang Zhu
-
Publication number: 20110118232Abstract: The invention relates to novel pyrimidine compounds of general formula (I), in which: A represents a group C?W or CRfRg; B represents a chemical bond or a group CRhRi; X represents O, S, a group N—Rk or a group CRmRn; D represents C?O or a chemical bond; E represents a linear or branched 2- to 10-membered alkylene chain that, as members of a chain, can have 1 or 2 non-adjacent heteroatom group(s) K, which is selected among O, S, S(O), S(O)2 and N—Rp and which can comprise a carbonyl group and/or a cycloalkanediyl group and/or a double or triple bond; W represents oxygen or sulfur; Z, together with the carbon atoms, to which it is bound, represents a condensed, optionally substituted 5-, 6- or 7-membered carbocyclic compound or heterocyclic compound that has 1, 2, 3 or 4 heteroatoms, which are selected among N, O and S; J represents CH2, CH2—CH2 or CH2—CH2—CH2; M represents CH or N; Y represents CH2, CH2—CH2 or CH2—CH2—CH2 or M-X, together, represent CH?C or CH2—CH?C; n is 0 or 1, and; Ra, Rb, Rc, Rd, Re, Rf,Type: ApplicationFiled: July 23, 2010Publication date: May 19, 2011Applicant: Abbott GmbH & Co. KGInventors: Hervè Geneste, Andreas Haupt, Wilfried Braje, Wilfried Lubisch, Gerd Steiner
-
Publication number: 20110112067Abstract: The invention provides compounds of the general formula (I) which are inhibitors of the human aldosterone synthase, and also pharmaceutical compositions containing these compounds, and a method of treating of hyperaldosteronism and/or disorders or diseases that are mediated by 11?-hydroxylase (CYP11B1) with these compounds.Type: ApplicationFiled: November 3, 2010Publication date: May 12, 2011Applicant: Universitat des SaarlandesInventors: Rolf W. Hartmann, Ralf Heim, Simon Lucas
-
Patent number: 7939521Abstract: The present invention relates to selected (R)-2-phenyl-propionamides and (R)-2-phenyl-sulfonamides with a hydrogen bond acceptor atom/group in a well defined position in the chemical space. These compounds show a surprising potent inhibitory effect on C5a induced human PMN chemotaxis. The compounds of the invention absolutely lack of CXCL8 inhibitory activity. Said compounds are useful in the treatment of pathologies depending on the chemotactic activation of neutrophils and monocytes induced by the fraction C5a of the complement. In particular, the compounds of the invention are useful in the treatment of sepsis, psoriasis, rheumatoid arthritis, ulcerative colitis, acute respiratory distress syndrome, idiopathic fibrosis, glomerulonephritis and in the prevention and treatment of injury caused by ischemia and reperfusion.Type: GrantFiled: December 13, 2005Date of Patent: May 10, 2011Assignee: DompePHA.R.MA S.p.A.Inventors: Marcello Allegretti, Riccardo Bertini, Andrea Beccari, Alessio Moriconi, Andrea Aramini, Cinzia Bizzarri, Francesco Colotta
-
Publication number: 20110105471Abstract: A form of crystalline (2S)-2-hydroxy-3-methyl-N-[(1S)-1-methyl-2-oxo-2-[[(1S)-2,3,4,5-tetrahydro-3-methyl-2-oxo-1H-3-benzazepin-1-yl]amino]ethyl]-butanamide anhydrate Form II having improved flowability and drug-loading properties and a process for its preparation.Type: ApplicationFiled: October 29, 2010Publication date: May 5, 2011Applicant: ELI LILLY AND COMPANYInventor: Christopher Luis BURCHAM
-
Publication number: 20110105472Abstract: Use of diaminopyrimidines of the formula (I) in which R1 to R11a,b,c and X1, X2 have the meanings given in the description, and also agrochemically active salts thereof as crop protection agents. Diaminopyrimidines of the formulae (Ia), (Ib) and (Ic) in which R8a, R8b, R8c, and R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, R11a,b,c and X1, X2 have the meanings given in the description, and also agrochemically active salts thereof and their use for controlling animal pests and/or phytopathogenic harmful fungi.Type: ApplicationFiled: March 16, 2009Publication date: May 5, 2011Applicant: Bayer CropScience AGInventors: Jörg Nico Greul, Olive Gaertzen, Stefan Hillebrand, Amos Mattes, Ulrike Wachendorff-Neumann, Peter Dahmen, Arnd Voerste, Peter Schreier, Ulrich Görgens, Heinz Kehne, Christian Paulitz, Hiroyuki Hadano, Oliver Guth, Angela Becker, Olga Malsam
-
Patent number: 7932382Abstract: The invention relates to conformationally constrained mimetics of Smac which function as inhibitors of Inhibitor of Apoptosis Proteins. The invention also relates to the use of these mimetics for inducing apoptotic cell death and for sensitizing cells to inducers of apoptosis.Type: GrantFiled: January 18, 2005Date of Patent: April 26, 2011Assignee: The Regents of the University of MichiganInventors: Shaomeng Wang, Haiying Sun, Zaneta Nikolovska-Coleska, Chao-Yie Yang, Liang Xu
-
Patent number: 7928223Abstract: Process for the synthesis of the compound of formula (I): Application in the synthesis of ivabradine, addition salts thereof with a pharmaceutically acceptable acid and hydrates thereof.Type: GrantFiled: June 17, 2009Date of Patent: April 19, 2011Assignee: Les Laboratoires ServierInventors: Jean-Michel Lerestif, Jean-Pierre Lecouve, Daniel Brigot
-
Patent number: 7888345Abstract: Benzazepinone compounds represented by Formula (I), or pharmaceutically acceptable salts thereof. Pharmaceutical compositions comprise an effective amount of the instant compounds, either alone, or in combination with one or more other therapeutically active compounds, and a pharmaceutically acceptable carrier. Methods of treating conditions associated with, or caused by, sodium channel activity, including, for example, acute pain, chronic pain, visceral pain, inflammatory pain, neuropathic pain, epilepsy, irritable bowel syndrome, urinary incontinence, pruritis, itchiness, allergic dermatitis, depression, anxiety, multiple sclerosis, and bipolar disorder, comprise administering an effective amount of the present compounds, either alone, or in combination with one or more other therapeutically active compounds.Type: GrantFiled: June 5, 2007Date of Patent: February 15, 2011Assignee: Merck Sharp & Dohme Corp.Inventors: Scott B. Hoyt, Clare London, Dong Ok, William H. Parsons
-
Patent number: 7879841Abstract: A ?d-crystalline form of ivabradine hydrochloride of formula (I): characterised by its powder X-ray diffraction data. Medicinal products containing the same which are useful as bradycardics.Type: GrantFiled: August 27, 2009Date of Patent: February 1, 2011Assignee: Les Laboratoires ServierInventors: Stephane Horvath, Marie-Noelle Auguste, Gerard Damien
-
Patent number: 7879842Abstract: ?-Crystalline form of ivabradine of formula (I): characterised by its powder X-ray diffraction diagram. Medicinal products containing the same which are useful as bradycardics.Type: GrantFiled: October 21, 2009Date of Patent: February 1, 2011Assignee: Les Laboratoires ServierInventors: Stephane Horvath, Marie-Noelle Auguste, Gerard Damien
-
Publication number: 20110015390Abstract: The present invention generally relates to a novel process for preparing vitronectin receptor antagonist compounds having a benzodiazepinyl core structure. This invention relates to the preparation of pharmaceutically active compounds which inhibit the vitronectin receptor and are useful for treatment of inflammation, cancer and cardiovascular disorders, such as atherosclerosis and restenosis, and diseases wherein bone resorption is a factor, such as osteoporosis. In particular, the present invention relates to a novel process for preparing (±)-3-oxo-8-{[3-(pyridin-2-ylamino)propyl]oxy}-2-(2,2,2-trifluoroethyl)-2,3,4,5-tetrahydro-1H-2-benzazepine-4-acetic acid, (R)-3-oxo-8-{[3-(pyridin-2-ylamino)propyl]oxy}-2-(2,2,2-trifluoroethyl)-2,3,4,5-tetrahydro-1H-2-benzazepine-4-acetic acid and (S)-3-oxo-8-{[3-(pyridin-2-ylamino)propyl]oxy}-2-(2,2,2-trifluoroethyl)-2,3,4,5-tetrahydro-1H-2-benzazepine-4-acetic acid or a pharmaceutically acceptable salt thereof.Type: ApplicationFiled: March 6, 2009Publication date: January 20, 2011Inventor: Matthew Allen Zajac
-
Patent number: 7872001Abstract: A ?d-Crystalline form of ivabradine hydrochloride of formula (I): characterised by its powder X-ray diffraction data. Medicinal products containing the same which are useful as bradycardics.Type: GrantFiled: August 27, 2009Date of Patent: January 18, 2011Assignee: Les Laboratoires ServierInventors: Stephane Horvath, Marie-Noelle Auguste, Gerard Damien
-
Publication number: 20110009385Abstract: A first aspect of the invention relates to a compound of formula (I), or a pharmaceutically acceptable salt, hydrate, complex or pro-drug thereof, wherein: R3 is selected from cyclopentyl and cyclohexyl; R9 is a substituted 5 or 6-membered aryl or heteroaryl group or a 6,5- or 6,6-fused biaryl or heterobiaryl group. Compounds of formula (I) exhibit surprisingly high dual efficacies for human cathepsin S and K and are useful for the treatment of rheumatoid arthritis, osteoarthritis, chronic obstructive pulmonary disease (COPD), atherosclerosis, cardiovascular diseases which exhibit significant damage and remodeling of extracellular matrix (ECM) and chronic pain.Type: ApplicationFiled: August 9, 2010Publication date: January 13, 2011Applicant: Amura Therapeutics LimitedInventors: MARTIN QUIBELL, John P. Watts, Nicholas S. Flinn